Boardroom Alpha
Meeting calendar
SLQT · Annual meeting · Tuesday, November 10, 2026

Selectquote Inc

3 nominees · 5 ballot items.

Stockholders will vote on the election of three Class I directors, ratification of Deloitte & Touche LLP as independent auditor, advisory approval of named executive officer compensation, approval of a 1-for-10 to 1-for-20 reverse stock split and corresponding authorized-share reduction, and approval of an adjournment if needed to solicit additional proxies for the reverse stock split.

Market cap
$79M
1Y TSR
-76.7%
Board grade
D
Record date
Sep 18, 2026
Filing
DEF 14A
Meeting concluded · Nov 10, 2026

Follow how the vote landed and what changed on Selectquote Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot5

  1. 1

    Election of Three Class I Directors

    ManagementBoard: FOR

    Elect Timothy R. Danker, Kavita K. Patel, and Christopher Wolfe to serve as Class I directors until the 2029 annual meeting or until their successors are elected and qualified.

  2. 2

    Ratification of Appointment of Deloitte & Touche LLP

    ManagementBoard: FOR

    Ratify the Audit Committee’s appointment of Deloitte & Touche LLP as SelectQuote’s independent registered public accounting firm for the fiscal year ending June 30, 2027.

  3. 3

    Non-Binding Advisory Vote to Approve Executive Compensation

    ManagementBoard: FOR

    Approve, on a non-binding advisory basis, the compensation of SelectQuote’s named executive officers as disclosed in the proxy statement.

    More detail

    The proposal asks stockholders to approve, on a non-binding advisory basis, the compensation paid to SelectQuote’s named executive officers. It covers compensation disclosed under Item 402 of Regulation S-K, including the compensation tables and related narrative discussion, rather than any single pay element or executive. The vote is advisory and does not legally bind the Company or the Compensation Committee. The company emphasizes that its program is designed to attract and retain executives, provide market-informed compensation, and align management with stockholder interests. A substantial portion of compensation is at risk and tied to annual financial performance and long-term equity value. For fiscal 2026, the program included cash incentives based on revenue, Adjusted EBITDA, operating cash flow, and individual performance, along with RSUs and price-vested units tied to stock-price hurdles. The Compensation Committee adjusted certain annual incentive targets after pharmacy benefit manager contract developments changed the reimbursement environment, while stating that plan rigor was maintained. SelectQuote reports that the prior year’s say-on-pay proposal received more than 96% support and that the Committee considered stockholder feedback in designing the current program. The Board recommends voting FOR because it believes the program rewarded strong operating results and continued to incentivize long-term value creation.

  4. 4

    Reverse Stock Split Proposal

    ManagementBoard: FOR

    Approve an amendment to the Certificate of Incorporation authorizing a 1-for-10 to 1-for-20 reverse stock split, at a ratio selected by the Board, together with a corresponding reduction in authorized common shares.

    More detail

    The proposal asks stockholders to approve an amendment to SelectQuote’s Certificate of Incorporation implementing a reverse stock split within a range of 1-for-10 to 1-for-20. The Board would select the final ratio after stockholder approval and could elect not to implement the transaction before filing the amendment. The amendment would also reduce the number of authorized common shares by the same ratio, and the company would not implement one component without the other. The principal stated objective is to increase the per-share trading price so SelectQuote can regain compliance with the NYSE’s continued-listing standards. The NYSE notified SelectQuote in March 2026 that its 30-trading-day average closing price was below $1.00 and provided a six-month cure period. If implemented, the company expects the price condition to be cured if the stock promptly exceeds $1.00 and remains above that level for at least 30 trading days, subject to NYSE review. Management also believes a higher share price could make the stock more acceptable to institutional and professional investors whose policies restrict low-priced securities. The filing cautions that a reverse split may fail to increase the price proportionately, may reduce liquidity, and may increase odd-lot transaction costs. Existing stockholders would generally retain the same proportional ownership, except for effects from cash paid in lieu of fractional shares, while stock-plan awards and exercise prices would be adjusted proportionately. The Board unanimously approved the amendment and recommends voting FOR, while retaining discretion to abandon the transaction if circumstances change.

  5. 5

    Adjournment Proposal

    ManagementBoard: FOR

    Approve, if necessary, adjournment of the Annual Meeting to solicit additional proxies supporting the reverse stock split proposal.

    More detail

    The proposal asks stockholders to authorize an adjournment of the Annual Meeting if additional time is needed to solicit proxies supporting the reverse stock split proposal. It is a contingent procedural measure rather than an authorization of a separate corporate transaction. The requested adjournment could be used if the reverse stock split vote appears insufficient or if additional solicitation would help secure approval. The filing states that stockholders who already submitted proxies may revoke them before those proxies are used during an adjourned meeting. Approval requires a majority of the votes present in person or represented by proxy and entitled to vote on the matter. Abstentions would have the same effect as votes against the adjournment proposal. The proposal is particularly connected to Proposal Four because the reverse stock split requires approval by a majority of all outstanding shares, a higher threshold than the ordinary majority of votes present standard. An adjournment could therefore provide the company an opportunity to obtain additional participation or affirmative votes for the reverse split. The Board recommends voting FOR to preserve flexibility to solicit additional proxies if necessary.

Director elections

Nominees on the ballot3

Ownership

Top institutional holders10

Latest 13F quarter
1ABRAMS BISON INVESTMENTS, LLC4.5%7,910,794$7M
2Mariner, LLC3.7%6,553,063$6M
3VANGUARD CAPITAL MANAGEMENT LLC3.5%6,110,257$5M
4AQR CAPITAL MANAGEMENT LLC1.4%2,429,449$2M
5CAPTRUST FINANCIAL ADVISORS1.3%2,354,276$2M
6Qube Research & Technologies Ltd1.2%2,148,653$2M
7Diametric Capital, LP1.1%1,969,167$2M
8BlackRock, Inc.1.1%1,906,631$2M
9MILLENNIUM MANAGEMENT LLC0.9%1,649,948$1M
10JANE STREET GROUP, LLC0.8%1,475,542$1M
Filings

Selectquote Inc proxy statements and SEC reports

Annual & quarterly reports (10-K, 10-Q)
Proxy statements (DEF 14A)
Reference

Frequently asked questions

When is the Selectquote Inc 2026 annual meeting?
Selectquote Inc (SLQT) holds its 2026 annual shareholder meeting on Tuesday, November 10, 2026.
What is the record date for the Selectquote Inc 2026 meeting?
The record date for the Selectquote Inc 2026 meeting is Friday, September 18, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Selectquote Inc's 2026 meeting?
The board is presenting 3 director nominees at the Selectquote Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Selectquote Inc 2026 meeting?
Shareholders will vote on 5 proposals at the Selectquote Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer